Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Marc Phelip

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Frontiers in Oncology|November 28, 2022
Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancerAdrien Grancher, Ludivine Beaussire, Sylvain Manfredi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Frontiers in Oncology|November 28, 2022
Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancerAdrien Grancher, Ludivine Beaussire, Sylvain Manfredi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
Pageof 12